HK1246641A1 - 緩釋性醫藥組合物 - Google Patents
緩釋性醫藥組合物Info
- Publication number
- HK1246641A1 HK1246641A1 HK18106001.4A HK18106001A HK1246641A1 HK 1246641 A1 HK1246641 A1 HK 1246641A1 HK 18106001 A HK18106001 A HK 18106001A HK 1246641 A1 HK1246641 A1 HK 1246641A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sustained
- pharmaceutical composition
- release pharmaceutical
- release
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055196 | 2015-03-18 | ||
| PCT/JP2016/058455 WO2016148228A1 (ja) | 2015-03-18 | 2016-03-17 | 徐放性医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246641A1 true HK1246641A1 (zh) | 2018-09-14 |
Family
ID=56919076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104433.7A HK1245083A1 (zh) | 2015-03-18 | 2018-04-03 | 緩釋性醫藥組合物 |
| HK18106001.4A HK1246641A1 (zh) | 2015-03-18 | 2018-05-09 | 緩釋性醫藥組合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104433.7A HK1245083A1 (zh) | 2015-03-18 | 2018-04-03 | 緩釋性醫藥組合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11090296B2 (zh) |
| EP (1) | EP3272362B1 (zh) |
| JP (2) | JP2016175900A (zh) |
| KR (2) | KR20230104762A (zh) |
| CN (1) | CN107427587A (zh) |
| AR (1) | AR105947A1 (zh) |
| CA (1) | CA2979971A1 (zh) |
| ES (1) | ES2969514T3 (zh) |
| HK (2) | HK1245083A1 (zh) |
| RU (1) | RU2704813C2 (zh) |
| TW (1) | TWI731853B (zh) |
| WO (1) | WO2016148228A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2969514T3 (es) * | 2015-03-18 | 2024-05-21 | Santen Pharmaceutical Co Ltd | Composición farmacéutica de liberación sostenida |
| US10682340B2 (en) | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
| JP7051721B2 (ja) | 2016-06-30 | 2022-04-11 | デュレクト コーポレーション | デポー製剤 |
| EA201990127A1 (ru) * | 2016-12-30 | 2020-08-18 | Дьюрект Корпорейшн | Депо-препарат |
| MX2020011535A (es) * | 2018-05-01 | 2020-11-24 | Chibi Inc | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |
| JP2021523223A (ja) * | 2018-05-01 | 2021-09-02 | チビ，インコーポレイティド | 眼への薬物の非侵襲的な持続型送達のための液体デポー |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001388A (en) * | 1973-06-14 | 1977-01-04 | Alza Corporation | Ophthalmological bioerodible drug dispensing formulation |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US20050281879A1 (en) * | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| US7544703B2 (en) | 2004-02-17 | 2009-06-09 | Santen Pharmaceutical Co., Ltd. | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
| MX344532B (es) | 2004-10-01 | 2016-12-19 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| KR20070083941A (ko) | 2004-10-04 | 2007-08-24 | 큐엘티 유에스에이, 인코포레이티드 | 중합체 전달 조성을 갖는 눈 전달 |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| BRPI0608152A2 (pt) * | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP5599705B2 (ja) | 2007-05-18 | 2014-10-01 | デュレクト コーポレーション | 改良されたデポー製剤 |
| KR20100055482A (ko) | 2007-08-16 | 2010-05-26 | 마커사이트, 인코포레이티드 | 안질환 또는 안이상의 치료를 위한 제제 |
| AU2010271746B2 (en) | 2009-07-17 | 2014-07-03 | Santen Pharmaceutical Co., Ltd. | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof |
| JP6339011B2 (ja) | 2011-06-10 | 2018-06-06 | ラムスコール インコーポレイテッド | 眼へのタンパク質の送出のための持続放出性製剤及びその調製方法 |
| WO2013153559A1 (en) | 2012-04-09 | 2013-10-17 | Scidose, Llc | Fulvestrant formulations |
| AU2014322111A1 (en) | 2013-09-20 | 2016-04-07 | Santen Pharmaceutical Co., Ltd. | Polyethylene glycol-containing composition |
| JP2016104708A (ja) * | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| ES2969514T3 (es) * | 2015-03-18 | 2024-05-21 | Santen Pharmaceutical Co Ltd | Composición farmacéutica de liberación sostenida |
| JP7051721B2 (ja) * | 2016-06-30 | 2022-04-11 | デュレクト コーポレーション | デポー製剤 |
| US10682340B2 (en) * | 2016-06-30 | 2020-06-16 | Durect Corporation | Depot formulations |
-
2016
- 2016-03-17 ES ES16765057T patent/ES2969514T3/es active Active
- 2016-03-17 CA CA2979971A patent/CA2979971A1/en active Pending
- 2016-03-17 RU RU2017134354A patent/RU2704813C2/ru active
- 2016-03-17 TW TW105108258A patent/TWI731853B/zh active
- 2016-03-17 KR KR1020237021936A patent/KR20230104762A/ko not_active Application Discontinuation
- 2016-03-17 AR ARP160100718A patent/AR105947A1/es unknown
- 2016-03-17 JP JP2016053405A patent/JP2016175900A/ja active Pending
- 2016-03-17 WO PCT/JP2016/058455 patent/WO2016148228A1/ja active Application Filing
- 2016-03-17 US US15/558,260 patent/US11090296B2/en active Active
- 2016-03-17 CN CN201680015702.4A patent/CN107427587A/zh active Pending
- 2016-03-17 KR KR1020177027688A patent/KR20170129170A/ko not_active Application Discontinuation
- 2016-03-17 EP EP16765057.1A patent/EP3272362B1/en active Active
-
2018
- 2018-04-03 HK HK18104433.7A patent/HK1245083A1/zh unknown
- 2018-05-09 HK HK18106001.4A patent/HK1246641A1/zh unknown
-
2020
- 2020-04-02 JP JP2020066353A patent/JP6955604B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3272362A4 (en) | 2018-12-05 |
| KR20170129170A (ko) | 2017-11-24 |
| ES2969514T3 (es) | 2024-05-21 |
| TWI731853B (zh) | 2021-07-01 |
| RU2017134354A3 (zh) | 2019-04-19 |
| JP6955604B2 (ja) | 2021-10-27 |
| EP3272362A1 (en) | 2018-01-24 |
| WO2016148228A1 (ja) | 2016-09-22 |
| KR20230104762A (ko) | 2023-07-10 |
| JP2016175900A (ja) | 2016-10-06 |
| TW201639569A (zh) | 2016-11-16 |
| HK1245083A1 (zh) | 2018-08-24 |
| EP3272362B1 (en) | 2023-12-13 |
| CA2979971A1 (en) | 2016-09-22 |
| RU2017134354A (ru) | 2019-04-03 |
| RU2704813C2 (ru) | 2019-10-31 |
| AR105947A1 (es) | 2017-11-29 |
| CN107427587A (zh) | 2017-12-01 |
| US20180042907A1 (en) | 2018-02-15 |
| JP2020117522A (ja) | 2020-08-06 |
| US11090296B2 (en) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265360B (en) | Pharmaceutical composition | |
| IL265260B (en) | pharmaceutical preparations | |
| GB201506658D0 (en) | Pharmaceutical compounds | |
| GB201504675D0 (en) | Pharmaceutical compounds | |
| GB201517217D0 (en) | Pharmaceutical compounds | |
| GB201506660D0 (en) | Pharmaceutical compounds | |
| GB201517216D0 (en) | Pharmaceutical compounds | |
| IL262654A (en) | Pharmacy preparation | |
| IL265349A (en) | Pharmaceutical composition | |
| HK1246641A1 (zh) | 緩釋性醫藥組合物 | |
| GB201506933D0 (en) | Pharmaceutical compounds | |
| GB201502567D0 (en) | Pharmaceutical compounds | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| HK1245073A1 (zh) | 藥物組合物 | |
| PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
| GB201615917D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| RS61548B1 (sr) | Farmaceutski sastav sa produženim oslobađanjem koji sadrži rivastigmin | |
| GB201615914D0 (en) | Pharmaceutical composition | |
| GB201615910D0 (en) | Pharmaceutical composition | |
| IL265436B (en) | Pharmacy preparation | |
| HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
| IL265428A (en) | Pharmaceutical composition |